PT - JOURNAL ARTICLE AU - Alvarez-Uria, Gerardo AU - Gandra, Sumanth AU - Gurram, Venkata R AU - Reddy, Raghu P AU - Midde, Manoranjan AU - Kumar, Praveen AU - Arce, Ketty E TI - Development and validation of the RCOS prognostic index: a bedside multivariable logistic regression model to predict hypoxaemia or death in patients with SARS-CoV-2 infection AID - 10.1101/2021.03.29.21254393 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.29.21254393 4099 - http://medrxiv.org/content/early/2021/04/06/2021.03.29.21254393.short 4100 - http://medrxiv.org/content/early/2021/04/06/2021.03.29.21254393.full AB - Previous COVID-19 prognostic models have been developed in hospital settings, and are not applicable to COVID-19 cases in the general population. There is an urgent need for prognostic scores aimed to identify patients at high risk of complications at the time of COVID-19 diagnosis. The RDT COVID-19 Observational Study (RCOS) collected clinical data from patients with COVID-19 admitted regardless of the severity of their symptoms in a general hospital in India. We aimed to develop and validate a simple bedside prognostic score to predict the risk of hypoxaemia or death.4035 patients were included in the development cohort and 2046 in the validation cohort. The primary outcome occurred in 961 (23.8%) and 548 (26.8%) patients in the development and validation cohorts, respectively. The final model included 12 variables: age, systolic blood pressure, heart rate, respiratory rate, aspartate transaminase, lactate dehydrogenase, urea, C-reactive protein, sodium, lymphocyte count, neutrophil count and neutrophil/lymphocyte ratio. In the validation cohort, the area under the receiver operating characteristic curve (AUROCC) was 0.907 (95% CI, 0.892-0.922) and the Brier Score was 0.098. The decision curve analysis showed good clinical utility in hypothetical scenarios where admission of patients was decided according to the prognostic index. When the prognostic index was used to predict mortality in the validation cohort, the AUROCC was 0.947 (95% CI, 0.925-0.97) and the Brier score was 0.0188.If our results are validated in other settings, the RCOS prognostic index could help improve the decision making in the current COVID-19 pandemic, especially in resource limited-settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the associated Ethics Committee of RDT Bathalapalli Hospital. Patient consent was waived because data were collected during routine clinical practice and the study analysis was performed with anonymised dataAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe conditions of the ethical approval for the study preclude open access data sharing to reduce the risk of patient identification. Specific requests for data sharing will be considered subject to ethical approval and data transfer agreements.